Efficacy and safety of add-on mirogabalin to conventional therapy for the treatment of peripheral neuropathic pain after thoracic surgery: the multicenter, randomized, open-label ADMIT-NeP study

Table 2 Change in VAS score at rest from baseline to Week 8 (MMRM analysis; mITT population)

Parameter	Mirogabalin add-on group (N = 62)	Conventional treatment group (N = 64)
LS mean change (95% CI) from baseline, mm	− 51.3 (− 54.9, − 47.7)	− 47.7 (− 51.2, − 44.2)
Difference in LS mean change (95% CI), mm	− 3.6 (− 8.7, 1.5)
P value^a	0.161	-

CI confidence interval, LS least squares, mITT modified intention-to-treat, MMRM mixed model for repeated measures, VAS Visual Analogue Scale
^avs. the conventional treatment group

ISSN: 1471-2407